Picard Medical Inc. (NYSE: PMI) reported a mixed second quarter for fiscal year 2026, ending June 30, as top-line growth significantly outpaced expectations while profitability metrics fell short of analyst forecasts.

The medical device manufacturer logged quarterly sales of $2.954 million, beating the analyst consensus estimate of $1.550 million by 90.58%. This represents a 38.62% increase over sales of $2.131 million in the same period last year. However, the company reported quarterly losses of $(3.05) per share, which missed the analyst consensus estimate of $(1.50) by 103.33%. This marks a 92.8% increase in losses compared to $(42.39) per share from the same period last year.

Financial Performance

The company’s financial results for the three and six months ended June 30, 2026, highlight a divergence between operational efficiency and overall profitability due to continued investment in research and administration.

For the first half of FY26, revenue increased 50% to $4.1 million, supported by strong U.S. product sales that partially offset lower European sales. Gross profit for the six-month period stood at $0.9 million, representing a gross margin of 21.7%, a marked improvement from the negative 17.7% margin recorded in the prior-year period.

Despite the operational gains, the net loss for the first half widened slightly to $13.3 million from $12.3 million in the previous year. This increase was attributed to higher research and development (R&D) and selling, general, and administrative expenses, which were partially offset by lower total other expenses.

What the Numbers Show

The divergence between the improving gross margin and the widening first-half net loss indicates that Picard Medical is currently in a high-investment phase. While the core SynCardia business has achieved unit economics that generate positive gross contribution (20.9% margin), the company’s operating leverage has not yet been realized. The R&D spend required for the next-generation Emperor Total Artificial Heart platform is absorbing the operational gains, suggesting that future profitability will depend on scaling revenue further or optimizing these discretionary costs.

Strategic Developments

Picard Medical continues to advance its next-generation technology alongside its commercial operations. Key strategic updates include:

• Emperor Total Artificial Heart: The company completed acute in vivo implant studies for the latest iteration of the Emperor platform. It also presented new in vivo data at the 2026 Annual Conference of the American Society for Artificial Internal Organs (ASAIO 2026).
• Engineering Architecture: Following the quarter-end, Picard publicly presented the integrated electromechanical drive architecture of the Emperor TAH at the IEEE EMBC 2026 conference, positioning it as a potential platform for a fully implantable total artificial heart.
• Manufacturing: Initiatives focused on improving manufacturing efficiency, quality control, and supply-chain resilience are ongoing to support both the SynCardia business and future growth.

Corporate Actions

In July 2026, the NYSE American accepted the company’s compliance plan, granting additional time to regain compliance with listing standards. Following stockholder approval at the Annual Meeting, Picard completed a 1-for-50 reverse stock split effective July 31, 2026. Management stated it is evaluating additional financing opportunities to support ongoing operations and future growth.

Picard Medical, Inc. (NYSE: PMI), parent company of SynCardia Systems LLC, marked a major development milestone by presenting the integrated architecture of its Emperor Total Artificial Heart (Emperor TAH) for the first time at the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (IEEE EMBC 2026). Held July 26-30 in Toronto, Canada, the event featured a poster presentation by Taha Hasekioglu, Director, Office of the COO & Emperor Program Lead, detailing how the patent-pending Emperor Drive System (EDS) integrates with clinically proven SynCardia Total Artificial Heart (STAH) ventricles. This public disclosure provides stakeholders with early visibility into the company’s roadmap toward future full implantability, building upon the existing STAH platform that has supported more than 2,100 implants across 27 countries.

The Emperor TAH represents the next evolution of total artificial heart technology, designed to replace the pneumatic drivers currently used with the SynCardia system with a compact electromechanical driver. By preserving the blood-contacting components—specifically the ventricles, diaphragm assemblies, chamber geometry, and mechanical valve interfaces—the company aims to leverage decades of clinical experience while advancing drive technology. The EDS is engineered to be smaller and self-confined, addressing limitations in portability and supporting the long-term goal of creating a fully implantable solution.

Presentation Details

Preclinical evaluations summarized in the presentation demonstrated physiologic preload-dependent output in Donovan mock circulation testing. The data also highlighted stable performance across clinically relevant afterload ranges and novel acute porcine implantation results that support anatomic compatibility and short-duration hemodynamic stability under electromechanical actuation. These findings underscore the engineering principles behind the patent-pending architecture.

What the Numbers Show

While no financial metrics were disclosed in this announcement, the strategic focus on the Emperor Drive System highlights a shift toward next-generation product development. SynCardia currently holds the position as the maker of the world’s first and only total artificial heart approved by the U.S. Food and Drug Administration (FDA) and Health Canada. With more than 2,100 implants performed at hospitals across 27 countries, the existing STAH platform remains the most widely used and extensively studied artificial heart globally. The introduction of the Emperor system suggests an effort to enhance or replace current drive mechanisms, potentially addressing limitations in portability or durability associated with earlier generations.

“The IEEE EMBC presentation represented an important milestone for the Emperor program because, for the first time, at the leading globally recognized forum for engineers, we were able to publicly share the integrated architecture of the Emperor TAH,” said Taha Hasekioglu. “The Emperor program is built on the foundation of the SynCardia Total Artificial Heart, and our approach has been to preserve the proven, blood-contacting components while advancing the drive technology that powers the system.”

Picard Medical expects to provide additional technical details regarding the system architecture following the conference. Participation at IEEE EMBC 2026 reflects the company’s commitment to advancing mechanical circulatory support through engineering innovation and scientific collaboration. Forward-looking statements in the release include expectations regarding the advancement of the Emperor TAH, regulatory submissions, and commercialization activities, subject to risks including the ability to obtain regulatory approvals and execute manufacturing initiatives.